Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665442 | 0.86 | TACR1 (0.48) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| SCHEMBL31332121 | 0.84 | EPHX1 (0.61) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| SCHEMBL3441407 | 0.83 | TACR1 (0.51) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| SCHEMBL3470972 | 0.83 | TACR1 (0.51) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL3472368 | 0.81 | TACR1 (0.50) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| SCHEMBL7276950 | 0.81 | CTNNB1 (0.53) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL7402726 | 0.81 | CTNNB1 (0.53) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| SCHEMBL3681421 | 0.80 | CYP1A2 (0.52) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| SCHEMBL1927058 | 0.80 | TDP1 (0.57) | CTNNB1TACR1TDP1CYP1A2CYP2C19 | |
| SCHEMBL2027675 | 0.80 | TDP1 (0.57) | CTNNB1TACR1TDP1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | claimed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | claimed |
| EP-2018859-A1 | Arylmethylene substituted N-acyl-beta-amino alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-28 | — | — | EP | claimed |
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| EP-2018859-A1 | Arylmethylene substituted N-acyl-beta-amino alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| EP-1673375-A2 | METHOD FOR THE IN SITU PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM OXAZABOROLIDINE-BORANE COMPLEXES, WHICH ARE USED IN ASYMMETRIC REDUCTION REACTIONS | PPG-Sipsy (FR) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035540-A2 | METHOD FOR THE IN SITU PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM OXAZABOROLIDINE-BORANE COMPLEXES, WHICH ARE USED IN ASYMMETRIC REDUCTION REACTIONS | PPG-SIPSY (FR) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | CTNNB1 3710/4885TACR1 1000/4885TDP1 3759/4885 |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | CTNNB1 2578/4885TACR1 4234/4885TDP1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.